Singapore National Eye Centre will NEVER ask you to transfer money over a call. If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg.

Corneal & External Eye Disease

Synonym(s):

Affiliated Links

The Department actively participates and contributes in regional and international organisations such as the Asia Cornea Society (ACS), Asian Eye Banking Association (AEBA), the Asia-Pacific Contact Lens Association of Ophthalmologists (APCLAO), and The Cornea Society.

In 2007, the Asia Cornea Society (ACS) was established in Singapore. The ACS is an organisation of corneal specialists throughout Asia. Headquartered at SNEC, the ACS has over 400 members from many Asian countries, including China, India, Japan, Korea, Taiwan, Philippines, and Thailand. Professor Donald Tan is the first and current President of the ACS.

In 2009, ACS established a subsidiary organisation, Asian Eye Banking Association (AEBA), to link Asian eye banks under a single umbrella organisation. AEBA aims to collaborate on developing unified Asian eye banking standards, educational programs in eye donation, and most importantly, to provide a network of exporting and sharing of corneal tissue throughout Asia.

The Asia-Pacific Contact Lens Association of Ophthalmologists is a society that brings together contact lens ophthalmologists in the Asia-Pacific region. The SNEC Cornea Department shares in APCLAO’s common vision among contact lens ophthalmologists and researchers throughout the Asia-Pacific region in promoting the exchange of knowledge on clinical, educational and research aspects of contact lenses with special relevance to the Asia-Pacific region. Dr Lim Li is the current APCLAO Secretary General and Dr Cordelia Chan is the current Treasurer.

Professor Donald Tan serves on the Board of Directors of The Cornea Society (formerly known as the Castroviejo Society, 1975). This is an illustrious international society which promotes the knowledge, research and understanding of the cornea, external eye disease and refractive surgery.

Our Care Team

Recent News

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."
30 Apr 2026 Read Story
Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.
05 Mar 2026 Read Story